Meyd-873 Verified

Produced by Moodyz, one of Japan’s largest and most prominent studios. Release Date: The title was released in early 2023.

| Model | Dosing Regimen | Tumor Growth Inhibition (TGI) | Key Observations | |-------|----------------|------------------------------|------------------| | | 30 mg/kg PO daily (4‑week course) | 93 % | Complete regression in 45 % of mice; durable response >8 weeks after treatment stop. | | Syngeneic Colon Cancer (KRAS‑G12D+/RAF‑low) | Same dose | 68 % | Partial response; suggests RAF‑dimer status enhances efficacy. | | Normal Tissue Toxicology (rat & dog) | 3× therapeutic exposure | No Grade ≥ 2 adverse events | No histopathologic changes in liver, kidney, heart, or bone marrow. | | Pharmacokinetic/Pharmacodynamic (PK/PD) | 30 mg/kg PO | >90 % target occupancy at 6 h; sustained >70 % at 24 h | Correlates tightly with tumor regression. | MEYD-873

— John D., 58, trial participant (fictional for illustration only) Produced by Moodyz, one of Japan’s largest and

MEYD‑873 represents a paradigm shift in neuro‑pharmacology: a that offers the spatial precision of optogenetics without the need for genetic manipulation, while retaining the pharmacokinetic advantages of conventional drugs. Its reversible, rapid kinetics, combined with an excellent safety profile, position it as a versatile platform for both therapeutic interventions and basic neuroscience research. If the upcoming clinical trials confirm its promise, MEYD‑873 could inaugurate a new class of photo‑pharmaceutics —drugs that are “turned on” only where and when clinicians or users desire them. | | Syngeneic Colon Cancer (KRAS‑G12D+/RAF‑low) | Same